Streetbeat News

Revenues

ACN

Accenture (NYSE:ACN) has outperformed the market over the past 10 years with an average annual return of 16.84%, resulting in a $100 investment growing to $472.15. The article highlights the power of compounded returns.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 6:30 pm

CNPOF

HITI

Cheech & Chong are opening their first cannabis shop in Maine, while new cannabis stores are also opening in Connecticut, New York, and Toronto. RIV Capital Inc. and High Tide Inc. are expanding their cannabis retail operations.

Portfolio Pulse from Jelena Martinovic

October 10, 2024 | 6:20 pm

BSFC

Blue Star Foods Corp. (NASDAQ: BSFC) has announced a significant agreement between its subsidiary, Taste of BC Aquafarms, and Miracle Springs to supply fingerlings. This partnership aims to accelerate harvest growth and boost production to 200 tons by 2025-2026, with projected revenues of CAD$2.315 million. The agreement is valued at CAD$200,000 and will help meet increasing market demand for sustainable seafood.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 6:02 pm

VITL

Vital Farms (NASDAQ:VITL) has been evaluated by 4 analysts over the past three months, with ratings ranging from bullish to indifferent. The average 12-month price target is $42.0, with a high of $48.00 and a low of $34.00. Recent analyst actions include a raised buy rating from DA Davidson and a lowered hold rating from Stifel. Vital Farms has shown strong financial performance with a 38.46% revenue growth rate, a net margin of 11.09%, and a debt-to-equity ratio of 0.09.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 6:01 pm

TXG

11 analysts have recently rated 10x Genomics (NASDAQ:TXG), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has dropped by 24.37% to $28.36. Analysts have adjusted their ratings and price targets, reflecting changing market dynamics and company performance. Despite positive revenue growth, the company faces challenges with low ROE and ROA.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 6:01 pm

NKE

Nike (NYSE:NKE) received mixed analyst ratings with a slight positive shift in average price targets. Analysts have adjusted their ratings and price targets based on recent market conditions and company performance. Despite a decline in revenue growth, Nike maintains strong financial metrics such as net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 6:00 pm

SIGI

Analysts have provided mixed reviews for Selective Insurance Group (NASDAQ:SIGI) over the past three months, with a recent decrease in the average 12-month price target. The company's financial metrics show strong revenue growth but challenges in profitability and returns.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 6:00 pm

GSK

IQV

PFE

GSK and Pfizer face declining sales of their RSV vaccines due to narrowed age recommendations by the CDC, impacting demand significantly. The vaccines are now recommended for adults aged 75 and above, and those aged 60-74 with certain chronic conditions. This has led to a drop in demand, with pharmacists reporting a two-thirds decrease compared to last year. GSK and Pfizer are relying on RSV vaccines to build new revenue streams as they face generic competition for their top-selling drugs.

Portfolio Pulse from Vandana Singh

October 10, 2024 | 6:00 pm

PH

Parker Hannifin (NYSE:PH) has outperformed the market over the past 20 years, achieving an average annual return of 14.02%. A $1000 investment in PH 20 years ago would now be worth $14,911.95. The article highlights the power of compounded returns over time.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 6:00 pm

MRK

MRNA

MYNZ

PFE

Pharmaceutical companies are focusing on personalized cancer therapies and immunotherapy as new strategies against cancer. Pfizer and Moderna are investing in mRNA technology for cancer treatment, while Merck has shown success with its Keytruda treatment. Mainz Biomed is advancing early cancer detection with its ColoAlert test.

Portfolio Pulse from Upwallstreet

October 10, 2024 | 6:00 pm